Literature DB >> 19578347

Urinary incontinence: oxybutynin topical gel for overactive bladder.

Christopher R Chapple.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19578347     DOI： 10.1038/nrurol.2009.111

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.

Authors:  Roger R Dmochowski; Victor Nitti; David Staskin; Karl Luber; Rodney Appell; G Willy Davila
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

2.  Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

Authors:  R A Appell; P Sand; R Dmochowski; R Anderson; N Zinner; D Lama; M Roach; J Miklos; D Saltzstein; T Boone; D R Staskin; D Albrecht
Journal:  Mayo Clin Proc       Date:  2001-04       Impact factor: 7.616

3.  A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.

Authors:  G W Davila; C A Daugherty; S W Sanders
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

4.  Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.

Authors:  K Waldeck; B Larsson; K E Andersson
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

5.  Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

Authors:  David R Staskin; Roger R Dmochowski; Peter K Sand; Scott A Macdiarmid; Kim E Caramelli; Heather Thomas; Gary Hoel
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

6.  Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

Authors:  Ananias C Diokno; Rodney A Appell; Peter K Sand; Roger R Dmochowski; Bernard M Gburek; Ira W Klimberg; Sherron H Kell
Journal:  Mayo Clin Proc       Date:  2003-06       Impact factor: 7.616

7.  Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.

Authors:  Rodney A Appell; Michael B Chancellor; R Howard Zobrist; Heather Thomas; Steven W Sanders
Journal:  Mayo Clin Proc       Date:  2003-06       Impact factor: 7.616

8.  Treatment of detrusor instability with oxybutynin rectal suppositories.

Authors:  H A Winkler; P K Sand
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 9.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Authors:  Christopher R Chapple; Vik Khullar; Zahava Gabriel; Dominic Muston; Caty Ebel Bitoun; David Weinstein
Journal:  Eur Urol       Date:  2008-06-20       Impact factor: 20.096

10.  Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.

Authors:  K M Hughes; J C Lang; R Lazare; D Gordon; S L Stanton; J Malone-Lee; M Geraint
Journal:  Xenobiotica       Date:  1992-07       Impact factor: 1.908
  10 in total
  1 in total

Review 1.  Oxybutynin topical gel in the treatment of overactive bladder.

Authors:  G Willy Davila
Journal:  Open Access J Urol       Date:  2010-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.